Condition
New Onset Diabetes After Transplant
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 2 (2)
P 4 (2)
Trial Status
Completed3
Unknown1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03642184Phase 4TerminatedPrimary
Efficacy and Safety of Empagliflozin in NODAT
NCT05240274Phase 2Completed
The POWERED Study: Prophylaxis With Metformin to Prevent PTDM
NCT03304626Phase 2Completed
Budesonide for Liver Transplant Immune Suppression
NCT04030013Not ApplicableCompletedPrimary
"Outcome of Diabetes Education Among Renal Transplant Recipients With New Onset Diabetes After Transplantation (NODAT)"
NCT01875224Phase 4UnknownPrimary
Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression
Showing all 5 trials